Kidney-disease player Chinook Therapeutics Inc. CEO Eric Dobmeier told BioWorld that the company's $65 million series A round provides "a few years of money at the current pace. I'm hopeful we're going to make progress, have really good use of proceeds, and be out there raising money again to advance the company, because there's just such a huge unmet need right now."